Clinical efficacy and safety of trimebutine combined with Shugan granule in the treatment of functional dyspepsia
10.13699/j.cnki.1001-6821.2016.06.006
- VernacularTitle:马来酸曲美布汀联合舒肝颗粒治疗功能性消化不良的临床疗效及安全性评价
- Author:
Hui-Ling YU
1
;
Su-Cai LU
;
Jie MENG
;
Yang-Yang WANG
;
Ying CHANG
;
Lu MEN
;
Rui GAO
;
Jing DING
Author Information
1. 河北大学 附属医院 消化科
- Keywords:
trimebutine;
Shugan granule;
functional dyspepsia;
clinical efficacy;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2016;32(6):499-501
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical efficacy and safety of tri-mebutine combined with Shugan granule in the treatment of functional dyspepsia.Methods A total of 84 patients with functional dyspepsia were randomly divided into control group ( n=42 ) and treatment group ( n=42 ).Control group was treated with trimebutine 0.2 g, tid for 4 weeks.Treatment group was treated with trimebutine 0.2 g, tid and Shu-gan granule 3 g, bid for 4 weeks.The clinical symptom scores, self -rating anxiety scale ( SAS ) and self -rating depression scale ( SDS ) scores, and incidence of adverse drug reactions were compared between the two groups.Results After treatment, the clinical symptom scores, SAS and SDS scores in treatment group were significantly lower than those in control group( all P<0.05).The incidence of adverse drug reactions in two groups has no significant difference( P>0.05).Conclusion The combined therapy of trimebutine and Shugan granule can significantly improve the clinical symptoms and the states of anxiety and depression without increasing of the incidence of adverse drug reactions.
